Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

Timing Is Everything

(2014) Julie Lampe et al.   Clinical Nurse Specialist

Closed-Loop System in the Management of Diabetes: Past, Present, and Future

(2014) Viral N. Shah et al.   Diabetes Technology & Therapeutics

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

(2014) Tim Heise et al.   Diabetes Therapy

Guideline for management of postmeal glucose in diabetes

(2013)   DIABETES RESEARCH AND CLINICAL PRACTICE

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Premeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes

(2010) Y. M. Luijf et al.   DIABETES CARE

Timing of Meal Insulin Boluses to Achieve Optimal Postprandial Glycemic Control in Patients with Type 1 Diabetes

(2010) Erin Cobry et al.   Diabetes Technology & Therapeutics

Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp

(2010) L. Heinemann et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus

(2008) Paolo Rossetti et al.   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY